Physician profile
Wallace B Purdy
NPI 1528166832
$2,485.03
in general payments reported to CMS, 2019-2025
22 companies · $745 in 2025
The $745 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $419 · 2021: $78.74 · 2022: $415 · 2023: $332 · 2024: $313 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,389 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,388.61 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $628.79 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $342.75 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $302.86 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $158.16 | 2022-2025 | |
| Esperion Therapeutics, INC. | $153.56 | 2023-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $134.06 | 2022-2023 | |
| Glaxosmithkline, LLC. | $129.33 | 2019-2024 | Trelegy Ellipta |
| Pfizer INC. | $119.56 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.47 | 2020-2022 | |
| Lilly USA, LLC | $84.76 | 2022-2025 | Mounjaro, Zepbound |
| Almatica Pharma LLC | $46.18 | 2024 | Loreev Xr |
| Corcept Therapeutics | $38.92 | 2020-2023 | Korlym |
| Antares Pharma, INC. | $38.65 | 2022 | |
| Abbott Laboratories | $37.91 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $34.21 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $28.13 | 2019 | |
| Aroa Biosurgery Incorporated | $28.04 | 2025 | |
| Sanofi-Aventis U.S. LLC | $20.98 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.29 | 2025 | Caplyta |
| Mylan Specialty L.P. | $14.87 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.76 | 2020 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wallace Purdy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.